Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Equinor ASA (EQNR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Equinor ASA — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Equinor ASA trades at $34.23 (market cap $77.42B). The key difference: Equinor ASA is far larger — about 17.2× ACADIA Pharmaceuticals Inc.'s market cap, and Equinor ASA pays a 4.48% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | EQNR | |
|---|---|---|
Market Cap | $4.49B | $77.42B |
Sector | Health | Energy |
52-Week High | $28.06 | $42.40 |
52-Week Low | $20.06 | $22.41 |
Enterprise Value | $3.69B | $89.19B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Equinor (EQNR) trades at $33.91, up 5.84% today, with a bearish technical signal despite recent earnings beats. The company shows solid cash flow from operations of $20.0B in 2025 and maintains a low EV/EBITDA of 2.21, but net income has declined to $5.04B. Recent strategic moves include acquiring BP's stake in Bay du Nord and expanding Norwegian gas production, while exiting non-core ventures like Japan offshore wind.
EQNR offers value with low valuation multiples and shareholder returns via dividends and buybacks, but faces risks from volatile energy prices and declining profitability. Analyst sentiment is mixed with 30% buy ratings, reflecting cautious optimism amid execution challenges and macroeconomic pressures on the oil and gas sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
